Skip to main content

Table 3 Two-year death rates according to patients' characteristics and exposure to revascularization and medication (n = 5596)

From: Revascularization and cardioprotective drug treatment in myocardial infarction patients: how do they impact on patients' survival when delivered as usual care

 

Total

2-year CV death

2-year non-CV death

Total

5596

603 (10.8%)

525 (9.4%)

Mean Age ± SD

5596

79.3 ± 7.3

77.0 ± 7.4

Gender

   

Women

2390

291 (12.2%)a

215 (9.0%)d

Men

3206

312 (9.7%)

310 (9.7%)

Comorbidity index

   

   Mean ± SD (median)

5596

2.6 ± 1.9 (2)

2.6 ± 2.1 (2)

   0

2012

83 (4.1%)b

89 (4.4%)b

   1–2

2077

227 (10.9%)

188 (9.0%)

   3–4

1111

197 (17.7%)

152 (13.7%)

   5–6

318

77 (24.2%)

72 (22.6%)

   ≥ 7

78

19 (24.4%)

24 (30.8%)

Revascularization

   

   No

4473

567 (12.7%)c

478 (10.7%)c

   Yes

1123

36 (3.2%)

47 (4.2%)

PTCA

767

24 (3.1%)d

33 (4.3%)d

CABG

356

12 (3.4%)

14 (3.9%)

Number of drug classes

   

   0

757

117 (15.5%)e

113 (14.9%)e

   1

1166

162 (13.9%)

136 (11.7%)

   2

2046

207 (10.1%)

178 (8.7%)

   3

1315

103 (7.8%)

78 (5.9%)

   4

312

14 (4.5%)

20 (6.4%)

  1. a The difference in CV death and in non-CV death rates between genders is statistically significant (p = .0003)
  2. b The difference in CV death and in non-CV death rates between Comorbidity index groups is statistically significant (p < 0.0001)
  3. c The difference in CV death and in non-CV death rates according to presence/absence of revascularization is statistically significant (p < 0.0001)
  4. d The difference in CV death and in non-CV death rates according to PTCA or CABG is not statistically significant (p > 0.05)
  5. e The difference in CV death and in non-CV death rates according to number of drugs classes claimed is statistically significant (p < 0.0001)
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us